Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We apply our discovery research to drive the development of new diagnostics and therapeutics in a range of chronic inflammatory and degenerative diseases including inflammatory arthritis, osteoarthritis, inflammatory bowel disease, fibrosis, cardiovascular disease and certain types of cancer. Using established or newly curated patient cohorts, we are performing tissue analysis, experimental medicine studies and clinical trials to discover and validate new therapeutic targets and biomarkers for patient stratification. Integral to this approach is the use of immune phenotyping and molecular technologies to redefine disease at the molecular level for the discovery of new disease-associated pathways.

Despite the recent discovery of exciting new molecular targets in a range of musculoskeletal and inflammatory diseases, there remains a time lag between the first identification that a target is effective and its adoption in clinical practise. To address this we recently launched the Arthritis Therapy Acceleration Programme to facilitate early adoption of new therapeutics across a range of clinically distinct inflammatory diseases. This approach will help us to identify effective interventions that treat the cause of disease as well as symptoms and ensure expensive treatments are targeted to those most likely to benefit.

Our work is supported by close relationships with the Nuffield Orthopaedic Centre, the Translational Gastroenterology Unit and other clinical departments within the Oxford University Hospitals NHS Foundation Trust and along the m40 corridor.

Groups within this theme